Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $18.92 in the prior trading day, Elanco Animal Health Inc (NYSE: ELAN) closed at $19.61, up 3.65%. In other words, the price has increased by $3.65 from its previous closing price. On the day, 5.01 million shares were traded. ELAN stock price reached its highest trading level at $19.695 during the session, while it also had its lowest trading level at $18.93.
Ratios:
Our goal is to gain a better understanding of ELAN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 18.08 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 26.99. For the most recent quarter (mrq), Quick Ratio is recorded 1.40 and its Current Ratio is at 2.60. In the meantime, Its Debt-to-Equity ratio is 0.62 whereas as Long-Term Debt/Eq ratio is at 0.61.
On December 09, 2024, UBS started tracking the stock assigning a Buy rating and target price of $18.UBS initiated its Buy rating on December 09, 2024, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Todd S and Jennifer G Young Li bought 49,333 shares for $16.82 per share.
Kurzius Lawrence Erik bought 10,000 shares of ELAN for $109,000 on Mar 07 ’25. The Director now owns 101,459 shares after completing the transaction at $10.90 per share. On Mar 11 ’25, another insider, Kurzius Lawrence Erik, who serves as the Director of the company, bought 10,000 shares for $10.20 each. As a result, the insider paid 102,000 and bolstered with 111,459 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELAN now has a Market Capitalization of 9742517248 and an Enterprise Value of 13412516864. As of this moment, Elanco’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.47, and their Forward P/E ratio for the next fiscal year is 19.81. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.04. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.17 while its Price-to-Book (P/B) ratio in mrq is 1.44. Its current Enterprise Value per Revenue stands at 2.991 whereas that against EBITDA is 15.929.
Stock Price History:
The Beta on a monthly basis for ELAN is 1.64, which has changed by 0.33492172 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, ELAN has reached a high of $19.35, while it has fallen to a 52-week low of $8.02. The 50-Day Moving Average of the stock is 14.58%, while the 200-Day Moving Average is calculated to be 49.14%.
Shares Statistics:
The stock has traded on average 7.00M shares per day over the past 3-months and 5764230 shares per day over the last 10 days, according to various share statistics. A total of 496.65M shares are outstanding, with a floating share count of 492.11M. Insiders hold about 0.95% of the company’s shares, while institutions hold 108.95% stake in the company. Shares short for ELAN as of 1757894400 were 27380854 with a Short Ratio of 3.91, compared to 1755216000 on 24292849. Therefore, it implies a Short% of Shares Outstanding of 27380854 and a Short% of Float of 7.62.
Earnings Estimates
As of right now, 10.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.13, with high estimates of $0.15 and low estimates of $0.11.
Analysts are recommending an EPS of between $1.0 and $0.85 for the fiscal current year, implying an average EPS of $0.89. EPS for the following year is $1.0, with 13.0 analysts recommending between $1.05 and $0.95.
Revenue Estimates
8 analysts predict $1.09B in revenue for . The current quarter. It ranges from a high estimate of $1.1B to a low estimate of $1.08B. As of . The current estimate, Elanco Animal Health Inc’s year-ago sales were $1.03BFor the next quarter, 8 analysts are estimating revenue of $1.08B. There is a high estimate of $1.09B for the next quarter, whereas the lowest estimate is $1.06B.
A total of 10 analysts have provided revenue estimates for ELAN’s current fiscal year. The highest revenue estimate was $4.62B, while the lowest revenue estimate was $4.58B, resulting in an average revenue estimate of $4.6B. In the same quarter a year ago, actual revenue was $4.44BBased on 11 analysts’ estimates, the company’s revenue will be $4.82B in the next fiscal year. The high estimate is $4.89B and the low estimate is $4.75B.
